Single-agent Ninlaro (ixazomib) as maintenance therapy in multiple myeloma following autologous stem cell transplant (ASCT) reduced the risk of disease progression or death by around a third versus placebo, new data from a major study with the Takeda Pharmaceutical Co. Ltd. drug show.
Detailed data from the TOURMALINE-MM3 trial presented to the 60th American Society of Hematology (ASH) meeting in San Diego should...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

